The use of remdesivir in patients with COVID-19
Date
2023
Authors
Afshar, Z.M.
Hosseinzadeh, D.
Hosseinzadeh, R.
Babazadeh, A.
Allahgholipour, A.
Sio, T.T.
Sullman, M.J.M.
Carson Chahhoud, K.
Barary, M.
Ebrahimpour, S.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Infectious Disorders - Drug Targets, 2023; 23(7, article no. e090523216697):1-13
Statement of Responsibility
Conference Name
Abstract
Remdesivir has appeared to be the most effective medication against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and is broadly administered to coronavirus disease 2019 (COVID-19) patients around the world. Remdesivir is an RNA polymerase inhibitor with a broad spectrum of antiviral activities against RNA viruses in in-vitro and in-vivo models of SARSCoV, the Middle East respiratory syndrome (MERS), and SARS-CoV-2. Remdesivir is the first Food and Drug Administration (FDA) approved anti-SARS-CoV-2 treatment for adult and pediatric patients and has been used for not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death. However, questions have been raised about the value of remdesivir in treating COVID-19, and governing bodies worldwide have been hesitant to approve this medication. Nevertheless, in the context of the public health emergency and the urgent need for effective treatments for patients with COVID-19, remdesivir has been approved by several authorities worldwide. Here, we discuss the characteristics and applications of remdesivir, and various challenging studies with different outcomes about its efficacy are also reviewed.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
Copyright 2022 Bentham Science Publishers